Dr. Montaner pioneered an innovative new concept called Treatment as Prevention (TasP) based on the notion that providing access to HAART at the earliest point following an HIV diagnosis could dramatically reduce the spread of HIV. The Lancet published a study led by Dr. Montaner presenting evidence supporting the efficiency of TasP in reducing new HIV cases.
The BC-CfE Laboratory is streamlining reporting processes for certain tests in order to simplify distribution and record-keeping, and to ensure completeness of results. Beginning September 2, 2025, results for the ‘Resistance Analysis of HIV-1 Protease and Reverse Transcriptase’ (Protease-RT) and ‘HIV-1 Integrase Resistance Genotype’ tests will be combined into a single ‘HIV-1 Resistance Genotype Report’.
For more details and example reports, please click on the button below
